ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Evinacumab shows promise in severe hypertriglyceridemia trial
May 18, 2021The investigational antibody evinacumab was able to lower triglycerides by up to 82 percent in severe hypertriglyceridemia patients with acute pancreatitis. -
FDA Accepts Evinacumab BLA for HoFH
August 17, 2020Regeneron Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a Biologics License Application (BLA) for evinacumab as an adjunct to other lipid-lowering therapies in patients with homozygous familial ... -
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
August 16, 2019Regeneron Pharmaceuticals, Inc. today announced positive pivotal Phase 3 results for evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody...
Pharma Sources Insight January 2025
